



**PRESS RELEASE
FOR IMMEDIATE RELEASE**

MEDICAGO ANNOUNCES FISCAL 2007 THIRD QUARTER RESULTS

Quebec City, Quebec – November 29, 2007 – Medicago Inc. (TSX-V: MDG), a developer and manufacturer of protein-based vaccines using a proprietary transient expression system, today reported its financial results for the third quarter ended September 30, 2007. The Company's financial statements and management report are available at www.sedar.com and at www.medicago.com.

"During the third quarter, we made significant progress in the validation of our key value proposition and delivered against milestones set out during the IPO," said Andy Sheldon, CEO of Medicago Inc. "We succeeded in using our proprietary expression technology to produce a vaccine candidate for H5N1 Avian Influenza in highly immunogenic particles called Virus like particles ("VLPs"). VLPs have significant advantages over conventional vaccines as they are known to enhance immunity and therefore increase protection against a disease. Further, we announced positive pre-clinical study results that demonstrated that our VLP vaccine triggers a strong protective immune response against the lethal H5N1 Indonesia strain currently in circulation. We are now performing additional studies that will allow the initiation of phase I studies in late 2008."

Financial Results

The Company's biggest challenge in the immediate short-term is to find partners for its technology and to raise additional capital to fund the ongoing activities of Medicago.

Research and development ("R&D") expenses decreased to \$582,000 in the third quarter of 2007, compared to \$941,000 in the third quarter of 2006. The decrease in R&D expenses is mainly attributable to a lower level of contract work and lower wages and salaries resulting from the Company's decision to focus on fewer, more promising opportunities.

General and administrative, business development and intellectual property expenses totalled \$465,000 for the third quarter of 2007, compared to \$612,000 for the same period in 2006.

Investment tax credits totalled \$468,000 for the three-month period ended September 30, 2007, compared to \$250,000 for the comparable period in 2006. The increase in tax credits resulted from the completion of a corporate reorganization in April 2007 and amendments to the Company's 2006 provincial tax returns.

Consolidated loss for the three months ended September 30, 2007, decreased to \$1,002,000 or (\$0.06) per share (basic and diluted), compared to a consolidated loss of \$1,784,000 or (\$0.16) per share (basic and diluted), for the same period in 2006.

As at September 30, 2007, the Company had consolidated assets of \$6.9 million, including cash and cash equivalents of \$127,000, compared to consolidated assets of \$8.6 million, including cash and cash equivalents of \$443,000, as at December 31, 2006.

About Medicago Inc.

Medicago is committed to provide highly effective and affordable vaccines based on our proprietary Virus-Like Particles (VLPs) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in the cells of non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It can deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

- 30 -

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information, contact:

Andy Sheldon
President and Chief Executive Officer
Medicago
Tel.: (418) 658-9393
Email: info@medicago.com

Arianna Vanin
The Equicom Group
Tel: (514) 844-4680
Email: avanin@equicomgroup.com